GeneDx Holdings (WGS) Asset Writedowns and Impairment (2021 - 2026)

GeneDx Holdings has disclosed Asset Writedowns and Impairment across 6 years of filings, most recently posting $31.3 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $31.3 million; the TTM figure through Mar 2026 stood at $31.3 million (up 22937.23% YoY), while the FY2023 annual figure was $3.9 million, up 247.82% from the prior year.
• Asset Writedowns and Impairment grew to $31.3 million in Q1 2026, from -$152000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for WGS reached as high as $174.5 million in Q4 2022 and fell as low as -$152000.0 in Q4 2025.
• The 5-year median for Asset Writedowns and Impairment is $123000.0 (2025), against an average of $19.7 million.
• Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 15652.58% — and 2024, when it tumbled 149.1%.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $174.5 million in 2022, then plunged by 99.84% to $279000.0 in 2023, then plunged by 149.1% to -$137000.0 in 2024, then slipped by 10.95% to -$152000.0 in 2025, then soared by 20683.55% to $31.3 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $31.3 million, -$152000.0, and $29000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.